First-generation Rheos® device lowered 24h blood pressure more, while second-generation Neo™ mainly reduced heart rate in resistant hypertension patients.
Does baroreflex activation therapy reduce 24h blood pressure and heart rate in patients with resistant hypertension, and how do first- and second-generation devices compare?
First-generation baroreflex activation devices provided better blood pressure reduction than second-generation devices in resistant hypertension, highlighting the impact of electrode design and implantation strategy.
Absolute Event Rate: 0% vs 0%
Baroreflex activation was safe and associated with reductions in 24h blood pressure and heart rate in patients with resistant hypertension. The first-generation Rheos® system demonstrated more pronounced blood pressure-lowering effects, whereas the second-generation Neo™ system was associated primarily with heart rate reduction without a significant effect on blood pressure. Although Rheos® is no longer commercially available, these findings highlight the importance of electrode design, implantation strategy, and patient selection in optimizing the efficacy of contemporary BAT.
Kaufeld et al. (Mon,) reported a other. First-generation Rheos® device lowered 24h blood pressure more, while second-generation Neo™ mainly reduced heart rate in resistant hypertension patients.